Ron Menezes takes over as president of Almirall's US subsidiary Aqua Pharma

22 August 2017

Spain’s largest drugmaker Almirall (ALM: MC) has appointed Ron Menezes as the new president and general manager of its USA-based subsidiary Aqua Pharmaceuticals.

He will be joining Aqua, which Almirall acquired in 2014 for around $327 million, in September and will bring with him broad experience in the field of dermatology in the USA, the largest and most important market in the world.

Eduardo Sanchiz, Almirall’s chief executive, commented: "We are very pleased to announce the appointment of Ron Menezes as the new president & GM of Aqua Pharmaceuticals reporting to Alfonso Ugarte, executive vice president of commercial strategy. “Ron’s incorporation and the experience he brings in dermatology represent a clear and undeniable opportunity to further strengthen this organization. Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK